-
-
7 . Periodical
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
- 저자
- by Rovin, Brad H; Barratt, Jonathan; Heerspink, Hiddo J L; Alpers, Charles E; Bieler, Stewart, et al.
- 소스
- The Lancet; December 2023, Vol. 402 Issue: 10417 p2077-2090, 14p